Literature DB >> 21292446

Arginine metabolism in soft tissue sarcoma.

Xiaofeng Yan, Masakazu Takahara, Lining Xie, Chisato Gondo, Nokitaka Setsu, Yoshinao Oda, Satoshi Takeuchi, Yating Tu, Yoichi Moroi, Masutaka Furue.   

Abstract

BACKGROUND: L-Arginine (L-Arg) is a conditionally essential amino acid for humans, which is the substrate for both arginase (ARG) and the inducible form of nitric oxide synthase (iNOS) enzymes. Whether L-Arg metabolism has detrimental or beneficial influence on the tumor growth depends on local up regulation of the NOS or ARG pathways at the tumor site.
OBJECTIVE: To evaluate the expression profile of ARG and iNOS in various histological subtypes of soft tissue sarcomas (STSs).
METHODS: A series of 81 adult STSs were tested for ARG1, ARG2 and iNOS expression by immunohistochemical analysis.
RESULTS: ARG1, ARG2 and iNOS expression was found in tumor cells of all cases of STSs except dermatofibrosarcoma protuberans (DFSP) in a cytoplasmic pattern. However, there was no significant correlation found between ARG, iNOS expression and histopathological parameters. Conversely, the majority of DFSP were devoid of ARG and iNOS expression, while only two cases showed focal and weak expression.
CONCLUSIONS: Overexpression of L-Arg-metabolizing enzymes ARG and iNOS in tumor cells of all of the STS cases except DFSP may have a role in mediating the biological processes which characterize STSs. New knowledge of the regulation of arginine metabolism in tumor tissues is key to designing sound therapeutic means to effectively prevent tumorigenesis. Further studies are needed to clarify the absence of ARG and iNOS staining in DFSP.
Copyright © 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292446     DOI: 10.1016/j.jdermsci.2010.12.009

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  4 in total

1.  An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.

Authors:  Seth D Goldstein; Masanori Hayashi; Catherine M Albert; Kyle W Jackson; David M Loeb
Journal:  Clin Exp Metastasis       Date:  2015-08-18       Impact factor: 5.150

2.  OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.

Authors:  Marcin Mikołaj Grzybowski; Paulina Seweryna Stańczak; Paulina Pomper; Roman Błaszczyk; Bartłomiej Borek; Anna Gzik; Julita Nowicka; Karol Jędrzejczak; Joanna Brzezińska; Tomasz Rejczak; Nazan Cemre Güner-Chalimoniuk; Agnieszka Kikulska; Michał Mlącki; Jolanta Pęczkowicz-Szyszka; Jacek Olczak; Adam Gołębiowski; Karolina Dzwonek; Paweł Dobrzański; Zbigniew Zasłona
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

3.  Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Authors:  Ashley Vardon; Madhumita Dandapani; Daryl Cheng; Paul Cheng; Carmela De Santo; Francis Mussai
Journal:  Oncotarget       Date:  2017-06-29

4.  Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma.

Authors:  Maximilian Lennartz; Eva Gehrig; Sören Weidemann; Natalia Gorbokon; Anne Menz; Franziska Büscheck; Claudia Hube-Magg; Andrea Hinsch; Viktor Reiswich; Doris Höflmayer; Christoph Fraune; Frank Jacobsen; Christian Bernreuther; Patrick Lebok; Guido Sauter; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Andreas H Marx; Ronald Simon; Till Krech; Till S Clauditz; Sarah Minner; David Dum; Ria Uhlig
Journal:  Diagnostics (Basel)       Date:  2021-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.